Swiss-based reproductive health start-up, Ava, has announced the birth of the first baby conceived with the help of its Ava fertility tracking sensor wearable.

US-based Ava user, Lizzie McGee, and her husband Sam welcomed their son, Jace McGee, on 11 July 2017, becoming the first confirmed ‘Ava baby’ born since the wearable’s launch in August 2016.

The couple found out about Ava after struggling for over a year to get pregnant with their second child.

“The experience of conceiving our first child was really difficult and stressful on our marriage, and I didn’t want to go through the same thing again with our second,” said Lizzie, who conceived Jace after wearing Ava for three months.

According to Ava Co-founder, Lea von Bidder, Lizzie is one of over one-third of Ava users who purchased the wearable to aid in conceiving a second child.

“Secondary infertility is much more common than many people realise, especially in cases where a couple has started their family later in life because it’s widely known that fertility decreases as maternal age increases,” said von Bidder.

“Ava helps women optimise their chances of conception at any age by identifying in real-time her full fertile window, not just the day of ovulation,” continued von Bidder.

Since its consumer launch, the Ava fertility tracking wearable has already helped over 500 women conceive. According to von Bidder, Ava users from across the US and Europe are reporting about 5-10 pregnancies a day.

The Ava wearable uses new technology to precisely detect the fertile days during a woman’s monthly cycle in real-time. Worn only at night while sleeping, Ava measures nine physiological parameters including pulse rate, breathing rate, heart rate variability, temperature that, in combination, help indicate a rise in reproductive hormones estradiol and progesterone. The impact of the rise of these hormones on the physiological parameters is used to detect a 5.3-day fertile window in a woman’s cycle.

Because users wear the Ava wearable at night and sync it with the Ava app in the morning, they are able to avoid the hassles, mess and invasiveness of other fertility tracking methods like ovulation strips and BBT thermometers.

An FDA Class 1 medical device, the Ava wearable was proven in a recently concluded clinical study at the University Hospital of Zurich to detect an average of 5.3 fertile days per cycle – in real-time – with 89% accuracy.

The company is also conducting clinical studies to adapt and expand its algorithms for use in pregnancy monitoring, and future use as a non-hormonal contraceptive device.

For more information contact, like us on Facebook or tweet us @eHealthNewsZA.